Minimum Requirements for Reporting Clinical Trials Evaluating the Therapeutic Potential of Platelet-Rich Plasma
January 2021
in “
Journal of The American Academy of Dermatology
”
TLDR The document sets guidelines to standardize reporting of PRP clinical trials for better reproducibility and comparability.
The document outlined the minimum requirements for reporting clinical trials evaluating the therapeutic potential of platelet-rich plasma (PRP). Key elements included initial blood volume, anticoagulant type, centrifugation parameters, PRP preparation and application methods, and detailed characterization of PRP components such as platelet size, red and white blood cell counts, and growth factor levels. Specifics for PRP application in treating androgenetic alopecia (AGA) were provided, including intradermal administration on the scalp with a dosage of 0.1-0.2 ml per injection/cm², administered in three doses at one-month intervals. The guidelines aimed to standardize reporting to improve the reproducibility and comparability of PRP clinical trials.
